Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Cost of RevenueEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsReceivables - NetReceivables - OtherShares Repurchased
Ratios

Corcept Therapeutics (CORT) EBIAT (2016 - 2025)

Corcept Therapeutics' EBIAT history spans 10 years, with the latest figure at $24.3 million for Q4 2025.

  • For Q4 2025, EBIAT fell 21.05% year-over-year to $24.3 million; the TTM value through Dec 2025 reached $99.6 million, down 29.44%, while the annual FY2025 figure was $99.7 million, 29.43% down from the prior year.
  • EBIAT for Q4 2025 was $24.3 million at Corcept Therapeutics, up from $19.7 million in the prior quarter.
  • Across five years, EBIAT topped out at $47.2 million in Q3 2024 and bottomed at $15.9 million in Q1 2023.
  • The 5-year median for EBIAT is $27.6 million (2023), against an average of $28.0 million.
  • The largest annual shift saw EBIAT soared 89.13% in 2023 before it crashed 58.34% in 2025.
  • A 5-year view of EBIAT shows it stood at $32.1 million in 2021, then crashed by 48.2% to $16.6 million in 2022, then surged by 89.13% to $31.4 million in 2023, then dropped by 2.09% to $30.7 million in 2024, then dropped by 21.05% to $24.3 million in 2025.
  • Per Business Quant, the three most recent readings for CORT's EBIAT are $24.3 million (Q4 2025), $19.7 million (Q3 2025), and $35.1 million (Q2 2025).